These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32140351)

  • 21. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder.
    Schmitt L; Tonnoir B; Arbus C
    Neuropsychobiology; 2006; 54(4):201-7. PubMed ID: 17337913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
    Bech P; Lönn SL; Overø KF
    J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of escitalopram and citalopram in outpatients with severe major depressive disorder: a prospective, naturalistic, 8-week study.
    Lançon C; Sapin C; Note I; Farisse J
    Int J Psychiatry Clin Pract; 2006; 10(2):131-7. PubMed ID: 24940963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of generic escitalopram (Lexacure(®)) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study.
    Jeong JH; Bahk WM; Woo YS; Lee KU; Kim DH; Kim MD; Kim W; Yang JC; Lee KH
    Neuropsychiatr Dis Treat; 2015; 11():2557-64. PubMed ID: 26504387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study.
    Woo YS; McIntyre RS; Kim JB; Lee MS; Kim JM; Yim HW; Jun TY
    Clin Psychopharmacol Neurosci; 2017 Nov; 15(4):391-401. PubMed ID: 29073751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial.
    Citrome L; Gommoll CP; Tang X; Nunez R; Mathews M
    Int Clin Psychopharmacol; 2015 Mar; 30(2):75-81. PubMed ID: 25396353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study.
    Tsai J; Thase ME; Mao Y; Ng-Mak D; Pikalov A; Loebel A
    CNS Spectr; 2017 Apr; 22(2):236-245. PubMed ID: 28357969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder.
    Katila H; Mezhebovsky I; Mulroy A; Berggren L; Eriksson H; Earley W; Datto C
    Am J Geriatr Psychiatry; 2013 Aug; 21(8):769-84. PubMed ID: 23567397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE; Franznick DA; Hollander SB; Fava M
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report.
    Kennedy SH; Lam RW; Rotzinger S; Milev RV; Blier P; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Giacobbe P; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; McInerney S; MacQueen GM; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Sassi RB; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Yu J; Uher R;
    J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30840787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
    Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repetitive transcranial magnetic stimulation for treatment of major depressive disorder with comorbid generalized anxiety disorder.
    White D; Tavakoli S
    Ann Clin Psychiatry; 2015 Aug; 27(3):192-6. PubMed ID: 26247218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Brown ES; Howard C; Khan DA; Carmody TJ
    Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Higher baseline serum adiponectin predicts better treatment remission in patients with generalized anxiety disorder treated with escitalopram.
    Shen Z; Wang F; Cui L; Ren L; Hong X; Yuan Y; Shen X
    Ann Palliat Med; 2021 Jul; 10(7):7634-7643. PubMed ID: 34353051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship of Apathy with Depressive Symptom Severity and Cognitive Functions in Geriatric Depression.
    Sözeri-Varma G; Bingöl C; Topak OZ; Enli Y; Özdel O
    Noro Psikiyatr Ars; 2019 Jun; 56(2):133-138. PubMed ID: 31223247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder.
    Moore N; Verdoux H; Fantino B
    Int Clin Psychopharmacol; 2005 May; 20(3):131-7. PubMed ID: 15812262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.
    Leinonen E; Skarstein J; Behnke K; Agren H; Helsdingen JT
    Int Clin Psychopharmacol; 1999 Nov; 14(6):329-37. PubMed ID: 10565799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review.
    Maneeton B; Maneeton N; Likhitsathian S; Woottiluk P; Wiriyacosol P; Boonyanaruthee V; Srisurapanont M
    Neuropsychiatr Dis Treat; 2018; 14():1953-1961. PubMed ID: 30122927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.